Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor

Estella M Davis, Jon T Knezevich, Robyn M Teply Department of Pharmacy Practice, Creighton University School of Pharmacy and Health Professions, Omaha, NE, USA Abstract: Antiplatelet therapy is widely used with proven benefit for the prevention of further ischemic cardiac complications in patients w...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Davis EM, Knezevich JT, Teply RM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/ba7c37b799db4eb3946220207dcfc116
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ba7c37b799db4eb3946220207dcfc116
record_format	dspace
spelling	oai:doaj.org-article:ba7c37b799db4eb3946220207dcfc1162021-12-02T00:57:36ZAdvances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor1179-1438https://doaj.org/article/ba7c37b799db4eb3946220207dcfc1162013-04-01T00:00:00Zhttp://www.dovepress.com/advances-in-antiplatelet-technologies-to-improve-cardiovascular-diseas-a12817https://doaj.org/toc/1179-1438Estella M Davis, Jon T Knezevich, Robyn M Teply Department of Pharmacy Practice, Creighton University School of Pharmacy and Health Professions, Omaha, NE, USA Abstract: Antiplatelet therapy is widely used with proven benefit for the prevention of further ischemic cardiac complications in patients with acute coronary syndrome. Treatment guidelines for acute coronary syndrome and percutaneous coronary intervention now recommend the use of oral antiplatelet agents including ticagrelor, prasugrel, or clopidogrel in combination with aspirin to comprise dual antiplatelet therapy for the prevention of recurrent ischemic events. The limitations of conventional antiplatelet therapy with clopidogrel or prasugrel include the potential for low response to clopidogrel identified through platelet reactivity or genetic testing, increased risk of bleeding with prasugrel, or slower return to normal platelet activity in patients who received either prasugrel or clopidogrel prior to emergent or planned surgical procedures. This review will discuss the pharmacokinetic and pharmacodynamic properties of ticagrelor in comparison to conventional P2Y12 receptor inhibitors and its utility in patients identified as low responders to clopidogrel. Completed clinical studies and substudies comparing ticagrelor to clopidogrel and ongoing clinical trials evaluating ticagrelor in acute coronary syndrome patients will also be reviewed. Keywords: ticagrelor, antiplatelet, acute coronary syndrome, ST elevation myocardial infarction, non-ST elevation MI, percutaneous coronary interventionDavis EMKnezevich JTTeply RMDove Medical PressarticleTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol 2013, Iss Issue 1, Pp 67-83 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950
spellingShingle	Therapeutics. Pharmacology RM1-950 Davis EM Knezevich JT Teply RM Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor
description	Estella M Davis, Jon T Knezevich, Robyn M Teply Department of Pharmacy Practice, Creighton University School of Pharmacy and Health Professions, Omaha, NE, USA Abstract: Antiplatelet therapy is widely used with proven benefit for the prevention of further ischemic cardiac complications in patients with acute coronary syndrome. Treatment guidelines for acute coronary syndrome and percutaneous coronary intervention now recommend the use of oral antiplatelet agents including ticagrelor, prasugrel, or clopidogrel in combination with aspirin to comprise dual antiplatelet therapy for the prevention of recurrent ischemic events. The limitations of conventional antiplatelet therapy with clopidogrel or prasugrel include the potential for low response to clopidogrel identified through platelet reactivity or genetic testing, increased risk of bleeding with prasugrel, or slower return to normal platelet activity in patients who received either prasugrel or clopidogrel prior to emergent or planned surgical procedures. This review will discuss the pharmacokinetic and pharmacodynamic properties of ticagrelor in comparison to conventional P2Y12 receptor inhibitors and its utility in patients identified as low responders to clopidogrel. Completed clinical studies and substudies comparing ticagrelor to clopidogrel and ongoing clinical trials evaluating ticagrelor in acute coronary syndrome patients will also be reviewed. Keywords: ticagrelor, antiplatelet, acute coronary syndrome, ST elevation myocardial infarction, non-ST elevation MI, percutaneous coronary intervention
format	article
author	Davis EM Knezevich JT Teply RM
author_facet	Davis EM Knezevich JT Teply RM
author_sort	Davis EM
title	Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor
title_short	Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor
title_full	Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor
title_fullStr	Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor
title_full_unstemmed	Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor
title_sort	advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/ba7c37b799db4eb3946220207dcfc116
work_keys_str_mv	AT davisem advancesinantiplatelettechnologiestoimprovecardiovasculardiseasemorbidityandmortalityareviewofticagrelor AT knezevichjt advancesinantiplatelettechnologiestoimprovecardiovasculardiseasemorbidityandmortalityareviewofticagrelor AT teplyrm advancesinantiplatelettechnologiestoimprovecardiovasculardiseasemorbidityandmortalityareviewofticagrelor
_version_	1718403405559365632

Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor

Ejemplares similares